Oragen Therapeutics addresses the $30B+ Inflammatory Bowel Disease (IBD) market with ORA-251, a first-in-class oral RNA therapy. While current treatments rely on systemic injections with significant side effects, ORA-251 delivers precision gene-silencing directly to the gut. This breakthrough is powered by a proprietary platform already validated in preclinical models to achieve rapid remission. By combining a high-value lead asset with a versatile delivery engine, Oragen Therapeutics creates multiple pathways to a high-impact strategic exit.
Prototype/preclinical
2.598.298€
2029-2030
Biotechnology
11%
1.000€
Share this project on your website.
Copy and paste the following code into your content.
Therapeutic RNA has demonstrated transformative clinical impact, yet oral delivery has remained a key bottleneck due to gastrointestinal degradation degradation and limited tissue targeting. Oragen removes this barrier with a patented oral delivery platform designed to achieve localized gut activity with minimal systemic exposure.
Oragen’s proprietary “nano-in-micro” platform combines:
Inflammatory bowel disease (IBD) is a chronic, relapsing inflammation of the gastrointestinal tract that causes debilitating symptoms (abdominal pain, diarrhea, bleeding, fatigue), reduced quality of life, and often hospitalization or surgery; it represents a major medical need and a >$30B global market, yet despite multiple biologics and small molecules, outcomes remain suboptimal and the unmet need is structural :
This backdrop supports strong commercial potential for therapies that can deliver higher remission rates, improved safety, and easier administration, particularly if they reduce systemic exposure while maintaining robust local activity.
Oragen Therapeutics’ lead program, ORA-251, is an orally administered siRNA candidate engineered for localized, precision gene silencing of a validated disease-driving target involved in intestinal inflammation.
RNA interference (RNAi) enables highly specific, sequence-driven silencing of a target gene, offering a level of precision and potency that can be difficult to achieve with other modalities such as antibodies or small molecules. Combined with localized intestinal delivery, ORA-251 aims to deliver deep activity at the site of disease while limiting systemic exposure, supporting a differentiated efficacy/safety profile and best-in-class potential.
Oragen Therapeutics’ lead program has achieved robust preclinical validation supported by extensive in vitro and in vivo studies:
Together, these results provide compelling evidence that oral delivery of therapeutic nucleic acids can achieve meaningful local pharmacology in the gut with a strong safety rationale.
Oragen is executing a structured CMC, non-clinical, and regulatory roadmap targeting clinical entry within ~3 years, with clear value inflection points.
The company is led by an experienced, complementary team spanning pharma development, nanomedicine, regulatory strategy, and business development, supported by senior experts. Governance is strengthened by top-tier boards including world-leading IBD experts Prof. Laurent Peyrin-Biroulet and Prof. Lucine Vuitton, and nanomedicine expert Prof. Alexander Kabanov.
Oragen Therapeutics offers a dual value engine: the ORA-251 drug candidate plus a proprietary oral delivery platform. This strategy multiplies partnering and M&A options in a market with strong deal activity and >$1B transaction benchmarks creating the potential for significant value creation and strong investor returns.
The global IBD market is valued at over $30B, yet it faces a critical stagnation: up to 40% of patients lose response to current biologics, while systemic immunosuppression limits long-term safety. The industry’s urgent need is for an oral alternative that matches biologic efficacy without the toxicity of systemic exposure.
Oragen Therapeutics targets this specific commercial gap. Rather than discovering new biology, the company de-risks its approach by using clinically validated targets and solving the primary bottleneck of RNA therapeutics: delivery. The investment case is anchored in three key differentiators:
1. Superior safety profile: Unlike competitors, Oragen’s “nano-in-micro” platform ensures the drug stays in the gut. Preclinical data confirms no systemic exposure, eliminating the safety risks that plague current injectable biologics.
2. Validated efficiency: The lead asset demonstrated tissue restoration to near-healthy levels within 3 days in vivo, proving that local gene silencing can outperform systemic treatments.
3. Strategic exit potential: The company is engineered for M&A. By developing a platform that can carry various RNA payloads, Oragen offers pharmaceutical partners a “plug-and-play” solution for the $47B IBD sector.
Supported by a team bridging pharma commercialization and academic excellence, and advised by top global KOLs like Pr. Peyrin-Biroulet, Oragen represents a high-conviction opportunity to back a first-in-class asset with a clear path to clinical validation.
Investment in Oragen involves specific technical and clinical risks. The most significant is translational, as the efficacy of oral siRNA must still be validated in human clinical trials. Additionally, the three-layer delivery platform introduces CMC complexity regarding large-scale stable manufacturing and formulation scale-up. Finally, the IBD sector is highly competitive, with a rapidly evolving pipeline of biologics and small molecules.
Already have an account? Please login here .
